Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Offers Free Early Dialogue For Anti-Bacterials, Anti-Fungals

Executive Summary

The European Medicines Agency hopes that its early interaction service will help strengthen the drug development pipeline for new antimicrobials.

You may also be interested in...



Simultaneous Early Scientific Dialogue On The Cards In Europe For Innovators

Regulators involved in the EU Innovation Network are working on a pilot aimed at sponsors, who want to have an early dialogue on product development issues with a national competent authority in Europe, but also want to get other NCAs or innovation offices involved.

EMA Explains Dos And Don’ts Of New Clinical Trials Portal

Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.

New Canadian Rule Allows Rolling Data Submissions For COVID-19 Drugs, Vaccines

The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel